CAPR

Capricor Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 2/10
  • Value↑ 6/10
Capricor Therapeutics sales and earnings growth
CAPR Growth
Fair
  • Revenue Y/Y↓ -100.00%
  • EPS Y/Y↓ -69.34%
  • FCF Y/Y↓ -141.57%
Capricor Therapeutics gross and profit margin trends
CAPR Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -200.96%
Capricor Therapeutics net debt vs free cash flow
CAPR Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -36.6

Capricor Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks